A Phase 3 Randomized Double Blind Placebo Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohns Disease

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Sasha Taleban
Sponsor
Merck and Company
Unit
Medicine